BOOT vs RUSHA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
BOOT exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating robust accounting strength, though the absence of an Altman Z-Score limits distress risk assessment. The company shows impressive profitability and growth, with 18.7% YoY revenue growth and 44.2% earnings growth, supported by strong margins and solid ROE of 18.74%. However, elevated valuation metrics, insider selling, and weakening near-term earnings momentum contrast with bullish analyst sentiment and strong long-term price performance. The stock trades above the Graham Number of $76.71 and below the growth-based intrinsic value of $195.29, suggesting a fair-to-slightly-rich valuation.
RUSHA exhibits strong operational health with a Piotroski F-Score of 7/9, indicating a robust financial foundation. However, the stock is significantly overvalued, trading at $73.93 despite a Graham Number of $46.02 and an Intrinsic Value of $22.89. While the company has an exceptional track record of beating earnings estimates over 25 quarters, current YoY revenue and earnings growth have turned negative (-11.8% and -11.0% respectively). The combination of a strong balance sheet and consistent execution is currently offset by expensive valuation metrics and bearish insider sentiment.
Compare Another Pair
Related Comparisons
BOOT vs RUSHA: Head-to-Head Comparison
This page compares Boot Barn Holdings, Inc. (BOOT) and Rush Enterprises, Inc. (RUSHA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.